Quick Answer
Cytek Biosciences, Inc. reported Stockholders Equity of $341.74 million for fiscal year 2025.
Cytek Biosciences, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $341.74M | -13.6% |
| 2024 | $395.74M | +0.7% |
| 2023 | $393.06M | -7.6% |
| 2022 | $425.55M | +5.0% |
| 2021 | $405.38M | +2629.2% |
| 2020 | -$16.03M | -138.4% |
| 2019 | $41.70M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $378.57M | -1.8% | +0.3% |
| June 30, 2025 | $377.56M | -3.0% | -0.5% |
| March 31, 2025 | $379.62M | -3.3% | -4.1% |
| December 31, 2024 | $395.74M | +0.7% | +2.7% |
| September 30, 2024 | $385.46M | -7.2% | -0.9% |
| June 30, 2024 | $389.12M | -8.3% | -0.9% |
| March 31, 2024 | $392.61M | -7.3% | -0.1% |
| December 31, 2023 | $393.06M | -7.6% | -5.4% |
- Cytek Biosciences, Inc. showed a decrease of -13.6% in Stockholders Equity compared to the prior fiscal year.
- Over the 2019–2025 period, Cytek Biosciences, Inc.’s stockholders equity has grown by 719.5% (from $41.70 million to $341.74 million).
- The most recent figure is from Cytek Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: